Sharon Barr is the Head of Research at Alexion Pharmaceuticals, a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. With 15 years of experience in precision medicine, she is responsible for the discovery and early development of Alexion's pipeline across its core therapeutic areas of hematology, nephrology, neurology, metabolics, cardiology, ophthalmology and acute care. Sharon also oversees the discovery and development of diagnostics, clinical biomarkers and bioanalytical sciences that support the company's efforts to deliver supportive technologies to people affected by rare diseases and devastating diseases. Previously, Sharon led the biomarkers team and global development team at Alexion. Prior to Alexion, she worked on the discovery and development of novel clinical biomarkers and companion diagnostics at Astellas Pharmaceuticals and OSI pharmaceuticals. Sharon received her Ph.D. from New York University and completed a postdoctoral fellowship at Stanford University.